LP
CRSP icon

LMR Partners’s CRISPR Therapeutics CRSP Stock Holding History

LMR Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680K Buy
+14,300
New +$754K ﹤0.01% 1048
2024
Q3 		– Sell
-28,600
Closed -$1.54M – 1337
2024
Q2 		$1.54M Buy
+28,600
New +$1.65M 0.01% 594

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LMR Partners's CRSP Position: Q1 2026 in Review

LMR Partners held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 5,000 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1173.

LMR Partners first reported a position in CRSP in Q2 2021 and has held it in 5 quarters since. The position peaked at $972K in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • LMR Partners held 5,000 shares of CRISPR Therapeutics worth $238K as of Q1 2026.
  • LMR Partners left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1173 holding.
  • LMR Partners first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • LMR Partners's CRISPR Therapeutics position peaked at $972K in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.